

ASX RELEASE

10 February 2016

## EXTENSION OF YISSUM LICENSE AGREEMENT INCLUDING TWO NEW PATENT APPLICATIONS FORMING A COMPREHENSIVE IP PORTFOLIO

**MMJ PhytoTech Limited (ASX:MMJ) (the “Company”)** is pleased to announce the extension of the exclusive Medicinal Cannabis (MC) licensing agreement between the Company’s Israeli subsidiary, Phytotech Therapeutics and Yissum, the commercialisation arm of the Hebrew University of Jerusalem, to include two new patent applications for oral delivery of medicinal cannabis.

### Development of a Comprehensive IP Portfolio

The extension of the exclusive licensing agreement with Yissum to include the addition of two new US provisional patent applications results in MMJ holding a comprehensive IP Portfolio for the oral delivery of MC. This enables MMJ to continue to develop a variety of cannabinoid based products for oral delivery with strong intellectual property protection.

### New Licenses: Water Soluble MC Formulations

The first additional licenced patent application added to the MMJ IP Portfolio comprises active combinations of THC and CBD in a dispersible concentrate. Upon contact with an aqueous solution, the concentrate forms nanometer range particle sizes. This licenced patent application extends the previously licensed US 7,919,113 for the delivery of two or more active MC compounds in a single dosage form with water solubility of cannabinoids with improved bioavailability of both compounds.

The second additional licensed patent application comprises dry, rapid water dispersible nanoparticles containing cannabinoids incorporated into a biodegradable polymer. This unique formulation offers high yield, extended release, high bio-availability and water solubility of cannabinoids. The composition may be delivered in oral, injectable, topical, inhaled and ear and eye drop formulations.

### Importance of Additional Licensed Patents

The two additional technologies licensed from Yissum extend MMJ’s IP portfolio and, importantly, expand the range of delivery technologies for the administering of MC to patients. This further strengthens MMJ’s position in the global Medicinal Cannabis market. The expansion of MMJ’s delivery technology portfolio for alternatives to smokeable form of Medicinal Cannabis is a key step in MMJ’s growth plans. Specifically, offering patients an alternative to the smokeable form of the product has the potential to significantly increase the size of the market MMJ is able to service.

### For more information please contact

Andreas Gedeon  
Managing Director  
+1 (250) 713 6302  
agedeon@mmj.ca

Gaelan Bloomfield  
Manager, Marketing & PR  
+61 431 303 567  
gbloomfield@mmj.ca

For media enquiries  
Market Eye  
Rob Gundelach, Director  
+61 424 930 789

## ASX RELEASE

---

### About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.

<http://www.mmjphytoTech.com.au>

For personal use only